down arrow

CNS Pharmaceuticals, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US18978H2013
USD
6.20
-0.32 (-4.88%)

Dec 24

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

6.026.25

52 Week

4.93114.00
Valuation
Technical
Day's Volume

CASH

42.19 k

Shareholding (Mar 2025)

FII

1.98%

Held by 3 FIIs

DII

97.47%

Held by 1 DIIs

Promoter

0.00%

How big is CNS Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, CNS Pharmaceuticals, Inc. has a market capitalization of 4.53 million, with net sales of 0.00 million and a net profit of -15.62 million over the last four quarters. The company reported shareholder's funds of 6.18 million and total assets of 8.70 million as of Dec 24.

Market Cap: As of Jun 18, CNS Pharmaceuticals, Inc. has a market capitalization of 4.53 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, CNS Pharmaceuticals reported net sales of 0.00 million and a net profit of -15.62 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 6.18 million and total assets of 8.70 million.

Read More

What does CNS Pharmaceuticals, Inc. do?

22-Jun-2025

CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company focused on developing anticancer drug candidates, particularly Berubicin for glioblastoma. It has a market cap of USD 4.53 million and reported a net profit loss of USD 4 million as of March 2025.

Overview: <BR>CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company focused on developing anticancer drug candidates for the treatment of brain and central nervous system tumors, specifically its lead drug candidate, Berubicin, for glioblastoma. The company operates within the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap with a market cap of USD 4.53 million.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -4 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 4.53 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.17 <BR>Return on Equity: -135.44% <BR>Price to Book: 0.41<BR><BR>Contact Details: <BR>Address: 2100 West Loop S Ste 900, HOUSTON TX: 77027-3522 <BR>Website: https://cnspharma.com/

Read More

Is CNS Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of May 1, 2025, CNS Pharmaceuticals, Inc. shows a mildly bearish trend overall, with mixed technical indicators and significant underperformance against the S&P 500, recording a year-to-date return of -87.79% compared to the S&P 500's 12.22%.

As of 1 May 2025, the technical trend for CNS Pharmaceuticals, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish overall, with key indicators showing mixed signals. The MACD is mildly bullish on both weekly and monthly time frames, while the RSI indicates a bullish monthly signal but no signal on the weekly. Bollinger Bands and moving averages are both mildly bearish on the weekly and daily time frames, respectively. Dow Theory presents a mildly bullish weekly view but is bearish on the monthly. <BR><BR>In terms of performance, the stock has significantly underperformed against the S&P 500 over the longer term, with a year-to-date return of -87.79% compared to the S&P 500's 12.22%, and a one-year return of -90.81% against the S&P 500's 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 4 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.91

stock-summary
Return on Equity

-117.78%

stock-summary
Price to Book

0.28

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-24.39%
0%
-24.39%
6 Months
-31.93%
0%
-31.93%
1 Year
-90.52%
0%
-90.52%
2 Years
-99.98%
0%
-99.98%
3 Years
183.11%
0%
183.11%
4 Years
-100.0%
0%
-100.0%
5 Years
-100.0%
0%
-100.0%

CNS Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0.00%
EBIT Growth (5y)
21.04%
EBIT to Interest (avg)
-16.88
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.17
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
6.13%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.52
EV to EBIT
0.48
EV to EBITDA
0.48
EV to Capital Employed
3.83
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
798.26%
ROE (Latest)
-135.44%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 2 Schemes (0.55%)

Foreign Institutions

Held by 3 Foreign Institutions (1.98%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 4.00% vs 37.50% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.40",
          "val2": "-2.50",
          "chgp": "4.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.40",
          "val2": "-2.50",
          "chgp": "4.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 21.16% vs -23.53% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-14.90",
          "val2": "-18.90",
          "chgp": "21.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-14.90",
          "val2": "-18.90",
          "chgp": "21.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-2.40
-2.50
4.00%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-2.40
-2.50
4.00%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 4.00% vs 37.50% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-14.90
-18.90
21.16%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-14.90
-18.90
21.16%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 21.16% vs -23.53% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About CNS Pharmaceuticals, Inc. stock-summary
stock-summary
CNS Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
CNS Pharmaceuticals Inc. is a preclinical stage pharmaceutical company. The Company is focused on developing anticancer drug candidates for the treatment of brain and central nervous system tumors. The Company is focused on developing its lead drug candidate, Berubicin for the treatment of glioblastoma. Glioblastoma are tumors that arise from astrocytes, which are star-shaped cells making up the supportive tissue of the brain. Berubicin is an anthracycline, a class of drugs that are among the chemotherapy drugs, which intercalates into Deoxyribonucleic acid (DNA) and interrupts topoisomerase II activity. It results in the inhibition of DNA replication and repair, and Ribonucleic acid (RNA) and protein synthesis.
Company Coordinates stock-summary
Company Details
2100 West Loop S Ste 900 , HOUSTON TX : 77027-3522
stock-summary
Tel:
stock-summary
https://cnspharma.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."